42,362 Organon & Co. $OGN Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue decreased its stake in Organon & Co. (NYSE:OGN) by 49.0% during the 3rd quarter, Holdings Channel reports. The firm owned 44,117 shares of the company’s stock after selling 42,362 shares during the quarter. State of Alaska Department of Revenue’s holdings in Organon & Co. were worth $604,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of OGN. Wedmont Private Capital boosted its holdings in Organon & Co. by 8.9% in the 3rd quarter. Wedmont Private Capital now owns 10,954 shares of the company’s stock worth $151,000 after buying an additional 899 shares during the last quarter. GAMMA Investing LLC increased its stake in Organon & Co. by 38.2% during the 3rd quarter. GAMMA Investing LLC now owns 7,990 shares of the company’s stock worth $109,000 after buying an additional 2,208 shares in the last quarter. Sequoia Financial Advisors LLC purchased a new stake in Organon & Co. during the 2nd quarter worth approximately $267,000. Tidal Investments LLC increased its stake in Organon & Co. by 18.1% during the 2nd quarter. Tidal Investments LLC now owns 285,099 shares of the company’s stock worth $3,860,000 after buying an additional 43,687 shares in the last quarter. Finally, WINTON GROUP Ltd purchased a new stake in Organon & Co. during the 2nd quarter worth approximately $6,904,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Five research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Reduce” and an average price target of $11.40.

Organon & Co. Trading Up 0.0%

Shares of Organon & Co. stock opened at $13.76 on Friday. The stock has a market cap of $3.61 billion, a P/E ratio of 17.86, a P/E/G ratio of 1.27 and a beta of 1.55. The stock’s 50 day simple moving average is $13.74 and its 200-day simple moving average is $13.03. Organon & Co. has a 1-year low of $5.69 and a 1-year high of $13.83. The company has a debt-to-equity ratio of 8.43, a current ratio of 1.95 and a quick ratio of 1.44.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 10th. Investors of record on Friday, August 14th were issued a $0.02 dividend. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, August 14th. Organon & Co.’s dividend payout ratio (DPR) is currently 10.39%.

Organon & Co. Company Profile

Organon & Co is a global health care company focused on improving the health and quality of life of women throughout their lives. The company develops, manufactures and commercializes prescription medicines and other health care products, with operations serving patients and health care providers in markets around the world.

Organon’s women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines and technologies related to fertility, pregnancy and other reproductive health needs.